Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Multiple Myeloma 186Lymphoma, Large B-Cell, Diffuse 41Leukemia, Lymphocytic, Chronic, B-Cell 41Recurrence 28Neoplasms, Plasma Cell 27Lymphoma 25Lymphoma, Mantle-Cell 23Lymphoma, Follicular 23Leukemia 20Lymphoma, B-Cell, Marginal Zone 15Lymphoma, Non-Hodgkin 14Leukemia, Myeloid, Acute 13Smoldering Multiple Myeloma 9Myelodysplastic Syndromes 9Lymphoma, T-Cell, Peripheral 7Lymphoma, B-Cell 7Waldenstrom Macroglobulinemia 6Neoplasms 6Neoplasm, Residual 6Immunoglobulin Light-chain Amyloidosis 6Lymphoma, T-Cell 5Leukemia, Plasma Cell 5Leukemia, Myelomonocytic, Chronic 5Renal Insufficiency 4Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell, Cutaneous 4Hodgkin Disease 4Hematologic Diseases 4Sezary Syndrome 3

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × Lenalidomide × Clear all
NCT00109005 2017-01-02

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
17 enrolled 11 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡